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 Abstract.  The treatment efficacy and effects of artesunate-mefloquine (AMQ) and mefloquine (MQ) on malaria-
associated anemia (MAA) were evaluated in 342 children ≤ 10 years of age with uncomplicated  Plasmodium falciparum 
malaria randomized to receive either drug/drug combination. All children recovered clinically. Fever clearance times were 
similar. Parasite clearance was significantly faster with AMQ (mean ± SD = 1.4 ± 0.6 days, 95% confidence interval [CI] = 
1.3–1.5,  P < 0.0001), but polymerase chain reaction–corrected cure rates were similar (97% versus 94%). Gametocyte car-
riage rates and the drug-attributable fall in hematocrit were significantly lower with AMQ (mean ± SD = 4.8 ± 3.8%, 95% 
CI = 3.6–6.0,  P = 0.03), but the rates of resolution of MAA were similar. Both regimens were well tolerated. AMQ clears 
parasitemia and reduces gametocyte carriage more rapidly and causes lesser fall in hematocrit than MQ, but both regi-
mens are effective treatment of uncomplicated  P. falciparum malaria in Nigerian children. 
 INTRODUCTION 
 The development and spread of drug resistance in  Plasmo-
dium falciparum to many antimalarials is of global con-
cern and a major public health problem in malaria-endemic 
countries in Africa. 1–4 As part of the strategy to combat the 
spread of antimalarial drug resistance globally, the World 
Health Organization recommended the use of artemisinin-
based combination therapies (ACTs) because they quickly 
reduce the burden of parasitemia and gametocytemia and 
the chance of drug resistance. 1,5–9 Artesunate-mefloquine 
(AMQ) combination is not considered a viable option for 
use as first-line therapy in Africa because of intense trans-
mission. 2 However AMQ, co-packaged as well as fixed dose 
formulations, is readily available and used in Africa. Despite 
high efficacy 9,10 and increasing use of ACTs in Africa, 11 many 
individuals still use antimalarial monotherapies because they 
are inexpensive and readily available, and the parasite has 
remained largely sensitive to, for example, mefloquine (MQ), 
despite the reported innate resistance to this drug in some 
areas of West Africa. 12,13 Additionally, the inverse relation-
ship in the sensitivity of  P. falciparum to MQ and chloroquine 
(CQ) in West Africa 14 has further renewed interest in the use 
of MQ, because high-grade CQ resistance is common in the 
sub-region. 
 Virtually all of the studies comparing AMQ with MQ have 
been conducted in areas of low transmission. 15 There is no 
reported study of the efficacy of AMQ versus MQ in African 
children living in areas of intense transmission despite the 
availability and ready use of artesunate and MQ in these areas. 
It is also unclear whether MQ-based ACTs have superior effi-
cacy to MQ alone in Africa, making it imperative to evaluate 
such regimens in sub-Saharan Africa. Such a study is essential 
as it may, in the future, influence policy and management of 
drug resistance in the community. 
 In this study, we report the tolerability, antimalarial treatment 
efficacy, effects on gametocyte carriage, and malaria-associated 
anemia of AMQ and MQ in children ≤ 10 years of age with 
acute, symptomatic, uncomplicated,  P. falciparum malaria. 
 MATERIALS AND METHODS 
 Study area.  The study was carried out in Ibadan, southwest 
Nigeria, from July 2007 to August 2008. In this area of hyperen-
demic malaria, transmission occurs all year round but is more 
intense during the rainy season from April to October. 16 
 In vitro and  in vivo MQ resistance of 14% and 0%, respectively, 
and  in vitro reduced susceptibility to artemisinin (the parent 
drug from which artesunate is derived) in 5% of  P. falciparum 
isolates in the area in the 1990s have been reported, 12–14,17 but 
there are no current estimates of failure rates. 
 Patients, treatment, and follow-up.  Patients were eligible to 
join the study if they were ≤ 10 years of age, had symptoms 
compatible with acute uncomplicated malaria such as anorexia, 
vomiting, or abdominal discomfort with or without diarrhea, 
with  P. falciparum parasitemia > 2,000 asexual forms/μL, a body 
(axillary) temperature > 37.4°C or history of fever in the 24–48 
hours preceding presentation, absence of other concomitant 
illness, no history of antimalarial use in the 2 weeks preceding 
presentation, negative urine tests for antimalarial drugs (Dill-
Glazko and lignin for 4-aminoquinolines and sulfonamides, 
respectively), 18,19 and written informed consent given by 
parents or guardians. Patients with severe malaria, 20 severe 
malnutrition, serious underlying diseases (renal, cardiac, or 
hepatic), and known allergy to study drugs were excluded from 
the study. The study protocol was reviewed and approved by 
the Ethics Committee of The Ministry of Health, Ibadan. The 
disease history, taken by the attending physician, was recorded 
by asking patients or their parents/guardians when the present 
symptomatic period started and was followed by a full physical 
examination by the same physician. 
 Enrolled patients were randomly assigned to receive AMQ 
or MQ. AMQ or MQ alone was given according to body 
weight: artesunate at a dose of 4 mg/kg daily at presentation 
(Day 0) and daily for a further 2 days (Days 1 and 2) and MQ 
at a dose of 25 mg/kg at presentation only. 
 All drugs were given orally as direct observed therapy by 
the physician. After drug administration, all patients waited 
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for at least 3 hours after to ensure the drug was not vom-
ited. If it was, the patient was excluded from the study. If 
necessary, patients were provided with antipyrectics (par-
acetamol tablets, 10–15 mg/kg every 8 hours for 24 hours). 
The randomization was computer generated, and treatment 
codes were sealed in individual envelopes. Patient evaluation 
and follow-up after drug administration was performed by 
another physician blinded to the drug treatment. The study 
nurse obtained thick and thin blood films from each child 
as soon as they came to the clinic. The slides were carefully 
labeled with the patients’ codes and were air dried before 
being stained. 
 Follow-up with clinical and parasitologic evaluation was 
done daily on Days 1–7 and then on Days 14, 21, 28, 35, and 
42. This consisted of enquiry about the patient’s well being, 
presence or absence of initial presenting symptoms, presence 
of additional symptoms, measurement of body temperature, 
heart and respiratory rates, and taking a blood smear for the 
quantification of parasitemia. 
 Side effects were defined as symptoms and signs that first 
occurred or became worse after treatment was started. Any 
new events occurring during treatment were also considered 
as side effects. 
 Thick and thin blood films prepared from a finger prick 
were stained with Giemsa and were examined by light micros-
copy under an oil-immersion objective, at ×1,000 magnifica-
tion, by two independent assessors who did not know the drug 
treatment of the patient. A senior member of the study team 
reviewed the slides if there was any disagreement between 
the microscopists. In addition, the slides of every third child 
enrolled in the study were reviewed by this senior member. 
Parasitemia (asexual or sexual) in thick films was estimated 
by counting asexual or sexual parasites relative to 1,000 leuko-
cytes, or 500 asexual or sexual forms, whichever occurred first. 
From this figure, the parasite density was calculated assuming 
a leukocyte count of 6,000/μL of blood. 
 Capillary blood collected before and during follow-up 
was used to measure packed cell volume (PCV). PCVs were 
measured using a microhematocrit tube and microcentrifuge 
(Hawksley, Lancing, UK). Drug-attributable fall in hemat-
ocrit (DAFH) during treatment was defined as the difference 
between patient’s hematocrit on Day 0 and Day 3 after start-
ing treatment. 
 Blood was spotted on filter papers on Days 0, 3, 7, 14, 21, 
28, 35, and 42 and at the time of treatment failures for par-
asite genotyping. Paired primary and post-treatment para-
sites were analyzed using parasite loci that exhibit repeated 
numbers of polymorphisms to distinguish true treatment 
failures from new infections. Briefly, Block 2 of merozoite 
surface protein-1 (MSP-1) and Block 3 of merozoite sur-
face protein-2 (MSP-2) and region II of glutamine-rich pro-
tein (GLURP) were amplified by two rounds of polymerase 
chain reaction (PCR) using primers and amplification condi-
tions described previously. 21–24 Ten microliters of the nested 
PCR products was resolved by electrophoresis on a 2% aga-
rose gel and sized against a 100-bp molecular weight marker 
(New England Biolabs, Beverly, MA). The banding pattern of 
the post-treatment parasites was compared with matched pri-
mary parasites in each of the patients who had parasitemia 
after treatment with either artesunate-mefloquine or meflo-
quine. Post-treatment and primary infection parasites show-
ing identical bands were considered as true treatment failure, 
whereas non-identity in banding patterns was considered as 
newly acquired infections. 
 Response to drug treatment was assessed using WHO 1973 
criteria 25 as follows: S, sensitive, clearance of parasitemia with-
out recurrence; RI (mild resistance), parasitemia disappears 
but reappears within 7–14 days; RII (moderate resistance), 
decrease of parasitemia but no complete clearance from 
peripheral blood; RIII (severe resistance), no pronounced 
decrease or increase in parasitemia at 48 hours after treat-
ment. In those with sensitive or mild resistance, parasite clear-
ance time was defined as the time elapsing between drug 
administration and absence of detectable parasitemia for at 
least 48 hours. Times taken to clear 50% and 90% parasitemia 
were calculated from the plot of decline in parasitemia ver-
sus time. Fever clearance time was defined as the time from 
drug administration until the body temperature fell to or 
< 37.4°C and remained so for 48 hours. Response to drug treat-
ment was also classified according to a modified version of the 
WHO 14-day  in vivo clinical classification system 26 ; because all 
patients were not febrile at enrollment, a temperature < 37.5°C 
was not an exclusion criterion for enrollment. The modifica-
tion also involved a follow up for 42 days in this area of intense 
transmission. The clinical classification system consisted of the 
following categories of response: adequate clinical and parasi-
tologic response (ACPR), late parasitologic failure (LPF), late 
clinical failure (LCF), and early treatment failure (ETF). 
 Cure rates were defined as the percentages of patients 
whose asexual parasitemia cleared from peripheral blood and 
who were free of patent asexual parasitemia on Days 14, 21, 
28, 35, and 42 of follow-up. The cure rates on Days 21–42 were 
adjusted on the basis of the PCR genotyping results of paired 
samples for patients with recurrent parasitemia after Day 14 
of starting treatment. 
 Re-treatment of drug treatment failures.  All patients failing 
treatment (within 35 days) with artesunate-mefloquine or 
mefloquine were retreated with these drug/drug combination 
and were followed for 63 days. Patients were re-treated 
whenever they became symptomatic (usually between 18 
and 35 days after initial enrollment). Patients with profound 
clinical (hyperpyrexia, oral fluid intolerance) and parasitologic 
deterioration (> 20% increase in baseline parasitemia) during 
follow-up were treated with parenteral quinine and were 
regarded as treatment failures. 
 Data analysis.  Sample size was calculated so that the 
study would be able to detect a 14% absolute difference in 
parasitologic failure “rate” between AMQ and MQ groups, 
with 99% power and at a 5% significance level. The expected 
treatment success rates were 99% for AMQ and 85% 
for MQ on Days 28–42. The sample size was 147 patients in 
each treatment arm. Data were analyzed using version 6 of 
the Epi-Info software 27 and the statistical program SPSS for 
Windows version 10.01. 28 Variables considered in the analysis 
were related to the densities of  P. falciparum gametocytes and 
trophozoites. Proportions were compared by calculating χ 2 
with Yates correction or by Fisher exact or Mantel Haenszel 
tests. Normally distributed, continuous data were compared 
by Student  t tests and analysis of variance (ANOVA). Data 
not conforming to a normal distribution were compared 
by the Mann-Whitney  U tests and the Kruskal-Wallis tests 
(or by Wilcoxon ranked sum test). All tests of significance, 
except where specifically indicated, were two-tailed.  P < 
0.05 was taken to indicate significant differences. Data were 
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(double)-entered serially using the patients’ codes and were 
only analyzed at the end of the study. 
 RESULTS 
 Patient characteristics.  Between July 2007 and August 2008, 
355 patients were recruited: 175 in the AMQ group and 180 in 
the MQ group ( Figure 1 ). There were 102 children < 5 years 
old: 56 (32%) in the AMQ group and 46 (25%) in the MQ 
group. Overall, 328 patients (166 in the AMQ group and 162 
in the MQ group) completed 42 days of follow-up; 13 children, 
4 in AMQ and 9 in MQ, were excluded because of failure to 
meet all inclusion criteria. Three hundred forty-two children 
completed at least 21 days of follow-up. Twelve children, five 
in the AMQ group and seven in the MQ group, could not be 
evaluated because of protocol violation or relocation from 
study area. Overall results are for 342 children. The baseline 
characteristics were similar for both treatment groups ( Table 1 ). 
However, mean hematocrit value was significantly lower in 
children enrolled in the AMQ treatment arm. 
 Fever and parasite clearance.  Two hundred thirty-seven 
children were febrile at enrollment: 120 in the AMQ group 
and 117 in the MQ group. On the whole, 120 of the children 
treated with AMQ and 117 of those treated with MQ received 
paracetamol during the first 24 hours. By Day 1, fever cleared 
in 99 and 94 children, respectively. There was no significant 
difference in the proportion of patients in whom fever cleared 
by Day 1 (χ 2 = 0.07,  P = 0.8). By Day 2, 6 and 16 children were 
still febrile in the AMQ and MQ groups, respectively (χ 2 = 4.3, 
 P = 0.03). However, overall, fever clearance was similar in the 
two treatment groups ( Table 2 ). 
 Compared with MQ, AMQ substantially accelerated the 
clearance of parasitemia. By Day 1, 11 children in the AMQ 
treatment arm and 67 children in the MQ treatment arm had 
not cleared their parasitemias. The difference in this propor-
tion was significant (χ 2 = 50.2,  P < 0.0001). Times to clear 50% 
 Figure 1 .  Trial profile. 
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and 90% parasitemia were significantly shorter, and overall, 
parasite clearance was significantly shorter in those treated 
with AMQ (1.4 ± 0.6 versus 2.1 ± 1.0 days,  P < 0.0001;  Table 2 ). 
No patient received rescue medication. 
 Response to both treatment regimens was not related to 
age: 1 of 56 and 7 of 115 < 5 and ≥ 5 year olds, respectively, 
treated with AMQ failed treatment by Day 28 ( P = 0.27, Fisher 
exact test). Similarly, 5 of 46 and 8 of 125 < 5 and ≥ 5 year olds, 
respectively, treated with MQ failed treatment by Day 28 ( P = 
0.33, by Fisher exact test). All 171 patients treated with AMQ 
and 168 of 171 patients treated with MQ had adequate clinical 
and parasitologic response (ACPR) up to Day 14. 
 Gametocyte carriage.  Gametocytes were detected in the 
peripheral blood in 108 children (31%) from the two treatment 
groups ( Table 3 ). The overall detection rate at enrollment 
was 12% and was not significantly different between the two 
treatment groups ( P = 0.71). After treatment, the emergence of 
gametocytes was significantly less frequent in the artesunate-
mefloquine group than in the mefloquine alone group ( P = 
0.004;  Table 3 ). Post-treatment, gametocyte carriage was 
significantly higher than pre-treatment in the mefloquine 
alone group ( P = 0.001) but not in the artesunate-mefloquine 
group ( P = 0.87;  Table 3 ). Analysis of daily gametocyte carriage 
rates showed that carriage was significantly lower from Days 
2 to 7 in those treated with AMQ compared with those treated 
with MQ ( P < 0.03 at all times). 
 Rate of re-appearance of parasitemia.  There were 28 
patients, 9 in the AMQ group and 19 in the MQ treatment 
group, in whom, after initial clearance, parasitemia reappeared 
between Days 7 or 14 and 42 ( Table 2 ). The cumulative 
proportion of children with  P. falciparum reappearance 
(recrudescence or re-infection) between 2 and 6 weeks after 
start of therapy was significantly lower with AMQ at 4 and 6 
weeks ( P < 0.05;  Table 2 ). All of the patients were symptomatic 
within 10 days of reappearance of parasitemia. 
 PCR findings.  Matched sample pairs collected before and 
after treatment from 27 of 28 patients in whom infections 
reoccurred after treatment with MQ and AMQ were success-
fully analyzed at MSP-1, MSP-2, and GLURP loci. Presence of 
different allelic families of MSP-1 and MSP-2 was often found 
in parasite DNA derived from a single patient, indicating a 
 Table 2 
 Therapeutic responses to artesunate-mefloquine or mefloquine 
AMQ MQ  P value
No. of patients 171 171 –
Fever clearance time (d) 
Mean ± SD 
Range 
95% CI
1.2 ± 0.6 
1–5 
1.1–1.4
1.3 ± 0.7 
1–4 
1.2–1.4
   0.23
No. of patient with 
parasitemia on day 1 
No. of patient with 
parasitemia on day 2
63 
11
104 
36
< 0.0001 
< 0.0001
Time to clear 50% 
parasitemia (d) 
Mean ± SD 
Range 
95% CI 
Time to clear 90% 
parasitemia (d) 
Mean ± SD 
Range 
95% CI 
Parasite clearance time (d) 
Mean ± SD 
Range 
95% CI
0.72 ± 0.02 
0.50–2.00 
0.7–0.8 
1.30 ± 0.04 
0.9–3.6 
1.2–1.4 
1.4 ± 0.6 
1–4 
1.3–1.5
0.97 ± 0.03 
0.5–2.5 
0.9–1.0 
1.74 ± 0.06 
0.9–4.5 
1.6–1.9 
2.1 ± 1.0 
1–5 
1.8–2.3
< 0.0000001 
< 0.0000001 
< 0.0001
Day and responses 
(S/RI/RII*†) 
14 
21 
28 
35 
42
171/0/0 
169/2/ 
166/5/ 
163/8/ 
162/9/
168/3/0 
165/6/ 
156/15/ 
154/17/ 
152/19/
0.24 
0.28 
0.038 
0.09 
0.048‡
ACPR§ 
LPF 
LCF 
ETF
162 
9 
0 
0
152 
10 
9 
0
PCR-corrected 
cure rate (%) 166 (97) 161 (94) 0.29
 Cure rates on Days 14, 21, 28, 35, and 42 for AMQ-treated children were 100%, 98.8%, 
97.1%, 95.3%, and 94.7%, respectively. For MQ, the corresponding values were 98.2%, 96.5%, 
91.2%, 90%, and 88.8%, respectively. 
 * PCR-uncorrected. 
 † No RII or RIII response in AMQ or MQ groups. 
 ‡ By Mantel-Haenszel test. 
 § Adequate clinical and parasitologic response (on Day 42). 
 AMQ = artesunate-mefloquine; MQ = mefloquine; LPF = late parasitologic failure; 
LCF = late clinical failure; ETF = early treatment failure. 
 Table 1 
 Demographic and clinical characteristics of patients at enrollment 
Variable AMQ MQ
 P 
value
No. of patients 171 171 –
Male/female 83/88 90/81 –
Age (months) 
Mean ± SD 
Range 
Number < 5 years
74.4 ± 34.8
6–120 
56
80.4 ± 34.8 
7–120 
46
0.11 
0.28
Weight (kg) 
Mean ± SD 
Range
18.5 ± 6.5 
7–46
19.7 ± 6.1 
7–36
0.07
Duration of 
illness (days) 
Mean ± SD 
Range
2.9 ± 1.1 
1–7
2.9 ± 1.1 
1–10
1.0
Temperature (°C) 
Mean ± SD 
Range 
Number > 40°C
38.3 ± 1.1 
36.2–40.9 
11
38.0 ± 1.8 
36.2–40.6 
10
0.06 
1.0
Parasite count (/μL) 
Geometric mean 
Range 
Number with 
> 250,000/μL
30,654 
2,484–884,571 
9
30,770 
2,400–1,402,635 
16
0.9
Gametocyte 
count (/μL) 
Geometric mean
Range
19 ( N = 22) 
6–216
23 ( N = 20) 
6–468
0.24
Hematocrit (%) 
Mean ± SD 
Range 
Number < 30%
31.1 ± 5.9 ( N = 119)
13–48 
43
32.8 ± 5.4 ( N = 126)
18–49
33
0.02 
0.12
 AMQ = artesunate-mefloquine; MQ = mefloquine. 
 Table 3 
 Gametocyte carriage in children with  P. falciparum malaria before 
and after treatment with mefloquine or artesunate-mefloquine 
Treatment group 
(no. of children)
No (%) of patients with gametocyte 
appearance
 P valueAt enrollment After enrollment Total
Mefloquine (171) 20 (11.4) 44 (25) 64 0.001
Artesunate-
mefloquine (171) 22 (12.6) 22 (12.6) 44 0.87
Total 42 (12) 66 (18.9) 108
983MEFLOQUINE AND COMBINATION ANTIMALARIAL TREATMENT
polyclonal infection. Ten of 18 (56%) paired pre- and post-
treatment samples obtained from patients who showed 
re-appearance of parasitemia after treatment with MQ showed 
identical allelic families of  msp-1 ,  msp-2, and  glurp , indicating 
genuine treatment failures. Paired samples from the remaining 
eight patients (44%) showed different allelic families of  msp-1 , 
 msp-2, and  glurp and were classified as newly acquired 
infections after MQ treatment. Polymorphic loci of  msp-1, 
msp-2, and  glurp in paired pre- and post-treatment samples of 
patients who showed reoccurrence of infections after treatment 
with AMQ confirmed genuine recrudescent infections in five 
of nine patients, whereas four were classified as newly acquired 
infections after genotyping. Overall, the PCR-corrected cure 
rate was 97% for AMQ and 94% for MQ. 
 Adverse events.  Overall, 44 children (32 boys and 12 girls), 
20 in the AMQ group and 24 in the MQ group, reported at least 
one adverse event within the first week of starting treatment. 
There was no significant difference in the proportions of 
patients reporting adverse events in both treatment groups 
(χ 2 = 0.43,  P = 0.51). However, the proportion of male children 
reporting adverse events was significantly higher than that of 
female children (χ 2 = 8.91,  P = 0.002). No child reported more 
than two adverse events. Many of the children reporting adverse 
events were > 5 years of age (24 of 44).  Table 4 is a summary 
of adverse events reported within the first week. Intravascular 
hemolysis (marked drop in hematocrit from 28% to 17% and 
hemoglobinuria) requiring hospitalization for 6 days occurred 
on Day 3 in a 6-year-old male child treated with AMQ. There 
were no other significant clinical findings in this patient. 
However, glucose-6-phosphate dehydrogenase (G6PD) status 
was not determined in the patient. Recovery was uneventful. 
All adverse effects were reversible, and there was no evidence 
of balance or hearing impairment attributable to artesunate. 
 Drug-attributable fall in hematocrit and resolution of 
anemia after treatment.  Hematocrit data were available in 245 
children, 119 in the AMQ group and 126 in the MQ group, at 
enrollment. Hematocrit values were available in 191 children, 
89 in the AMQ group and 102 in the MQ group, on both Days 
0 and 3, and these were used for the assessment of DAFH. 
In these children, there was no change in hematocrit values 
between Days 0 and 3 in seven and nine children, respectively, 
in the AMQ and MQ groups. In 15 and 10 children in the 
AMQ and MQ groups, respectively, there was an increase in 
hematocrit values between days 0 and 3. In 66 and 83 children 
in the AMQ and MQ groups, respectively, there was a decrease 
in hematocrit values between days 0 and 3. There were no 
significant differences in these proportions between the two 
treatment groups. DAFH was significantly greater in MQ- than 
AMQ-treated children (6.1 ± 4.5; 95% CI = 5.2–7.0 versus 4.8 ± 
3.9%; 95% CI = 3.6–6.0;  P = 0.03;  Figure 2 ). In general, the rates 
of rise in hematocrit in the two treatment groups were similar 
after Day 3 ( Figure 2 ). 
 Overall, 76 children were considered anemic (PCV < 30%) 
at presentation: 43 in the AMQ group and 33 in the MQ group. 
Ten of the 76 children with anemia were gametocyte carriers 
at presentation, whereas 18 of the 169 children without ane-
mia were gametocyte carriers at presentation. The difference 
between the two proportions was not significant (χ 2 = 0.39,  P = 
0.53).  Table 5 is a summary of the rate of resolution of anemia 
after treatment in 66 children in whom complete data were 
available from Days 0 to 42. These rates were similar for both 
treatment groups. 
 Re-treatment of treatment failures.  Of the 28 children with 
reappearance of parasitemia during follow-up, 7 each were 
retreated with AMQ or MQ. In all children, parasitemia cleared 
 Table 4 
 Adverse events reported within the first week of the study 
AMQ MQ
No. of children 171 171
Adverse event
Pruritus 0 2
Vomiting 8 14
Abdominal pain 6 6
Weakness 2 1
Sleeplessness 2 2
Diarrhea 1 2
Headache 0 1
Icterus 0 1
Intravascular hemolysis 1* 0
Excessive salivation 0 2
 * Male child 6 years of age, G-6-PD status not determined; required hospitalization. 
 AMQ = artesunate-mefloquine; MQ = mefloquine. 
 Table 5 
 Resolution of malaria-associated anemia after treatment 
AMQ MQ P value
No. with PCV < 30% 34 ( N = 108) 32 ( N = 112) 0.74
Mean PCV (%) 
and [range] 24.9 [17–29] 25.2 [18–29]
No of males (%) 20 (58.8.1) 16 (50) 0.50
Age (months) 
Mean ± SD 
Range 
Number < 60 months
61.5 ± 35.4 
12–120 
16
67.9 ± 36.5 
10–132 
12
1.0 
0.59
Parasite count (/μL) 
Geometric mean 
Range
46,183 
2,800–503,200
51,399 
6,900–346,875
No. with gametocytemia 
at presentation (%) 3 (5.3) 7 (12.2) 0.36
No with PCV < 30(%) 
Day 7 
Day 14 
Day 21 
Day 28 
Day 35 
Day 42
13 ( N = 24) 
7 ( N = 16) 
3 ( N = 13) 
5 ( N = 11) 
2 ( N = 9) 
3 ( N = 9)
15 ( N = 19) 
4 ( N = 14) 
2 ( N = 7) 
1 ( N = 7) 
3 ( N = 8) 
1 ( N = 6)
0.17 
0.63 
1.0* 
0.31* 
0.61* 
0.6*
 *  Fisher exact test. 
 AMQ = artesunate-mefloquine; MQ = mefloquine. 
 Figure 2 .  Changes in hematocrit before, during, and after treatment 
with artesunate-mefloquine (0) and mefloquine (×) in children with 
falciparum malaria. 
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within 2 days and did not recur during another 42 days of 
follow-up. PCR analysis showed that these were re-infections. 
 DISCUSSION 
 Both AMQ and MQ proved to be effective treatments for 
acute, uncomplicated  P. falciparum malaria in this endemic 
area where innate resistance to MQ was reported > 20 years 
ago. 12,13 The insignificant decline in MQ efficacy compared 
with the findings 20 years ago and despite the reported innate 
resistance could be because of a number of reasons. First, as 
previously suggested, 14 there may be a lack of predictive value 
of performance  in vivo by in  vitro data. Second, there may be 
a play of the inverse relationship in sensitivity  in vitro in iso-
lates of  P. falciparum to MQ and CQ, 14,29 because CQ resis-
tance is currently high grade in the area. 30 Third, until recently, 
the very limited use of MQ in the area since the early 1990s 
may have allowed restoration of sensitivity to isolates with 
reduced sensitivity  in vitro . Thus, the efficacy of MQ in the first 
2 weeks after starting treatment, in very young children, in this 
study is nearly similar to that in the same area almost 20 years 
ago. 17 However, there was a significant decline in efficacy after 
2 weeks, indicating MQ-resistant parasites are present in the 
area. In very young children from another endemic setting in 
West Africa, the efficacy of this drug has been compromised 
because of low blood levels after oral administration. 31 
 As anticipated, the results with AMQ were better than with 
MQ alone despite the relative absence of a significant decline 
in  in vivo sensitivity to MQ. The initial rapid responses, charac-
terized by significantly rapid clearance of asexual parasitemia 
with AMQ were clearly caused by the artemisinin derivative, 
artesunate. The latter ensured rapid recovery and reduced the 
risk of reappearance of parasitemia and prevented the risk 
of deterioration to severe malaria that may sometimes occur 
with slow-acting schizonticides. The artesunate in AMQ also 
significantly reduced the intensity of gametocytemia, as pre-
viously reported by others, 32–34 which may contribute to pre-
vent transmission of the infection. Although this impact may 
not be readily obvious in areas of intense transmission, 35 there 
may be significant impact on malaria incidence in areas of 
low transmission. 7,36 The sensitivity of  P. falciparum to AMQ 
seems encouraging in the very few areas of Africa where it has 
been evaluated and in many areas elsewhere. 32,34,37–41 However, 
in certain areas, for example, along Cambodia–Thailand and 
northwestern border of Thailand, the efficacy of AMQ is 
declining primarily because of resistance to MQ. 42,43 Recently, 
artemisinin resistance has been reported in Cambodia. 44 Thus, 
close monitoring will be needed with the use of AMQ in those 
areas of West Africa where reduced  in vitro susceptibility has 
been reported to MQ and artemisinin 13 and where patients are 
more likely to take the artesunate and leave the MQ compo-
nent or the possibility of providers selling one drug to reduce 
costs in co-packaging now available in many endemic areas of 
West Africa. In addition, the long half-life of mefloquine poses 
a risk of selection of resistant parasites later in the recovery 
phase when dug levels are low. 
 Except for possibly drug-related intravascular hemo-
lysis, both drug treatments seem well tolerated. In general, 
many of the reported adverse events could be attributable 
to MQ and were indistinguishable from those of malaria; all 
were reversible. There was no evidence of balance or hear-
ing impairment attributable to artesunate. The overall rate 
of adverse effects was 13% and was significantly higher in 
older children and in boys. This rate may be an underestimate 
because younger children are less likely to volunteer adverse 
effects compared with older children. Adverse effects of 
MQ, for therapy or prophylaxis, are usually more frequent in 
girls 45–50 but may be unrelated to drug levels. 48 It was surpris-
ing that adverse effects were more common in male children 
and the reasons are unclear. Sex-related difference in drug 
metabolism has been described for a number of drugs 51 but 
not for MQ when administered with or without artesunate 
in non-pregnant women. However, such differences, if they 
exist, may lead to higher blood levels in the male child and 
may explain the higher rate of side effects. Hormonal factors 
may also contribute to this difference. In contrast to that seen 
in adults from the same area after MQ treatment, 52 adverse 
central nervous side effects were uncommon in the children 
evaluated. 
 Despite a significantly higher mean hematocrit value at 
enrollment in children treated with MQ, MQ produced a sig-
nificantly greater fall in hematocrit during treatment com-
pared with AMQ. This would suggest that the spleen may not 
destroy all parasitized red blood cells whose parasites have 
been killed by AMQ. This finding lends support to that of 
Chotivanich and others, 53 who showed that artemisinin deriva-
tives may selectively kill parasites without the spleen destroy-
ing the red cells containing the dead parasites. However, it is 
possible that the addition of MQ to artesunate may attenuate 
the favorable effects of artesunate alone on red cell preserva-
tion during the removal of dead parasites as has been shown 
for the addition of amodiaquine to artesunate. 54 
 Overall, 4% of all anemic children at enrollment were still 
anemic 4–6 weeks after starting therapy. Despite a significantly 
higher drug-associated fall in hematocrit in MQ-treated chil-
dren, this rate of recovery was not influenced by artesunate—
an observation consistent with that of others from another 
endemic area in Africa. 55 This would suggest that other fac-
tors contributing to the anemia seen in children with uncom-
plicated  P. falciparum malaria need to be explored. 
 Received July 13, 2009. Accepted for publication August 27, 2009. 
 Acknowledgments:  We are grateful to our clinic staff, especially Moji 
Amao and Deboyin Lawal, for assistance with running the study. 
 Authors’ addresses: Akintunde Sowunmi, Grace O. Gbotosho, 
Christian Happi, Titilope Okuboyejo, Onikepe Folarin, Sulayman 
Balogun, and Obaro Michael, Department of Pharmacology and 
Therapeutics, University of Ibadan, Ibadan, Nigeria. 
 Reprint requests: Akintunde Sowunmi, Department of Clinical 
Pharmacology, University College Hospital, Ibadan, Nigeria 2053, 
E-mail: akinsowunmi@hotmail.com. 
 REFERENCES 
  1.  World Health Organization, 2001.  The Use of Antimalarial Drugs. 
Report of a WHO Technical Consultation . Geneva: World 
Health Organization. 
  2.  World Health Organization, 2001.  Antimalarial Drug Combination 
Therapy. Report of a WHO Technical Consultation . Geneva: 
World Health Organization. 
  3.  Trape J-F, Pison G, Preziosi M-P, Enel C, Du Lou AD, Delaunay V, 
Samb B, Lagarde E, Molez J-F, Simondon F, 1998. Impact of 
chloroquine resistance on malaria mortality.  Life Sci 321: 
689–697. 
  4.  Trape JF, 2001. The public health impact of chloroquine resistance 
in Africa.  Am J Trop Med Hyg 64 (Suppl 1–2): 12–17. 
985MEFLOQUINE AND COMBINATION ANTIMALARIAL TREATMENT
  5.  White N, 1999. Antimalarial drug resistance and combination che-
motherapy.  Phil Trans R Soc Lond Series B 354: 739–749. 
  6.  Hien TT, White NJ, 1993. Qinghaosu.  Lancet 341: 603–608. 
  7.  Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, 
Chongsuphajasiddhi T, White NJ, 1996. Effects of artemisinin 
derivatives on malaria transmissibility.  Lancet 347: 1654–1658. 
  8.  Price R, van Vugt M, Nosten F, Luxemburger C, Brockman A, 
Phaipun L, Chongsuphajaisiddhi T, White NJ, 1998. Artesunate 
versus artemether for the treatment of recrudescent multi-drug 
resistant falciparum malaria.  Am J Trop Med Hyg 59: 883–888. 
  9.  Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse 
M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, 
Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui P-B, 
Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, 
Rezbach P, Some E, Taylor WRJ, 2002. Amodiaquine-artesunate 
versus amodiaquine for uncomplicated  Plasmodium falciparum 
malaria in African children: a randomised, multicentre trial. 
 Lancet 359: 1365–1372. 
 10.  Sowunmi A, Fehintola FA, Adedeji AA, Gbotosho GO, Tambo E, 
Fateye BA, Happi TC, Oduola AMJ, 2005. Open randomized 
study of artesunate-amodiaquine vs. chloroquine-pyrimethamine-
sulfadoxine for the treatment of uncomplicated  Plasmodium 
falciparum malaria in Nigerian children.  Trop Med Inter Hlth 10: 
1161–1170. 
 11.  Mokuolu OA, Okoro EO, Ayetoro SO, Adewara AA, 2007. Effect 
of artemisinin-based treatment policy on consumption pattern 
of antimalarials.  Am J Trop Med Hyg 76: 7–11. 
 12.  Oduola AMJ, Milhous WK, Salako LA, Walker O, Desjardins RE, 
1987. Reduced  in vitro susceptibility to mefloquine in West 
African isolates of  Plasmodium falciparum from Nigeria. 
 Lancet ii: 1304–1305. 
 13.  Oduola AMJ, Sowunmi A, Milhous WK, Kyle DE, Martin RK, 
Walker O, Salako LA, 1992. Innate resistance to new antima-
larial drugs in  Plasmodium falciparum from Nigeria.  Trans R 
Soc Trop Med Hyg 86: 123–126. 
 14.  Sowunmi A, Oduola AMJ, Salako LA, Ogundahunsi OAT, Laoye 
OJ, Walker O, 1992. The relationship between the response of 
 Plasmodium falciparum malaria to mefloquine in African chil-
dren and its sensitivity  in vitro.  Trans R Soc Trop Med Hyg 86: 
368–371. 
 15.  Bukirwa H, Orton L, 2005. Artesunate plus mefloquine versus 
mefloquine for treating uncomplicated malaria.  Cochrane 
Database Syst Rev 4: CD004531. 
 16.  Salako LA, Ajayi FO, Sowunmi A, Walker O, 1990. Malaria in 
Nigeria: a revisit.  Ann Trop Med Parasitol 84: 435–445. 
 17.  Sowunmi A, Salako LA, Walker O, Ogundahunsi OAT, 1990. Clini-
cal efficacy of mefloquine in children suffereing from chloro-
quine-resistant  Plasmodium falciparum malaria in Nigeria. 
 Trans R Soc Trop Med Hyg 84: 761–764. 
 18.  Lilijveld J, Kortmann H, 1970. The eosin colour test of Dill and 
Glazko: a simple field test to detect chloroquine in urine.  Bull 
Wld Health Org 42: 477–479. 
 19.  World Health Organization, 1986.  Chemotherapy of Malaria. 
Second Edition. Geneva: World Health Organization. 
 20.  World Health Organization, 2000. Severe falciparum malaria. 
 Trans R Soc Trop Med Hyg 94 (Suppl 1): 1–90. 
 21.  Happi TC, Thomas SM, Gbotosho GO, Falade CO, Akinboye DO, 
Gerena L, Hudson T, Sowunmi A, Kyle DE, Milhous W, Wirth 
DF, Oduola AMJ, 2003. Point mutations in the  pfcrt and  pfmdr-1 
genes of  Plasmodium falciparum and clinical response to chlo-
roquine, among malaria patients from Nigeria.  Ann Trop Med 
Parasitol 97: 439–451. 
 22.  Happi CT, Gbotosho GO, Sowunmi A, Falade CO, Akinboye DO, 
Gerena L, Kyle DE, Milhous W, Wirth DF, Oduola AMJ, 2004. 
Molecular analysis of  Plasmodium falciparum recrudescent 
malaria infections in children treated with chloroquine in 
Nigeria.  Am J Trop Med Hyg 70: 20–26. 
 23.  Happi CT, Gbotosho GO, Folarin OA, Akinboye DO, Yusuf BO, 
Ebong OO, Sowunmi A, Kyle DE, Milhous W, Wirth DF, Oduola 
AMJ, 2005. Polymorphism in  Plasmodium falciparum dhfr and 
 dhps genes and age related  in vivo sulfadoxine pyrimethamine 
resistance in malaria-infected patients from Nigeria.  Acta Trop 
95: 183–193. 
 24.  Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, 
Kyle DE, Milhous W, Wirth DF, Oduola AMJ, 2006. Association 
between mutations in  Plasmodium falciparum chloroquine resis-
tance transporter and  P. falciparum multidrug resistance 1 genes 
and  in vivo amodiaquine resistance in  P. falciparum malaria-
infected children in Nigeria.  Am J Trop Med Hyg 75: 155–161. 
 25.  World Health Organization, 1973.  Chemotherapy of Malaria and 
Resistance to Antimalarials . Geneva: World Health Organization. 
 26.  World Health Organization, 2003.  Assessment and Monitoring of 
Antimalarial Drug Efficacy for the Treatment of Uncomplicated 
Falciparum Malaria. Geneva: World Health Organization. 
 27.  Anonymous, 1994.  Epi Info Version 6. A Word Processing Data 
Base and Statistics Program for Public Health on IBM-
compatible Microcomputers . Atlanta, GA: Centers for Disease 
Control and Prevention. 
 28.  Anonymous, 1999.  SPSS for Windows Release 10.01 (Standard 
Version) . Chicago, IL: SPSS. 
 29.  Wernsdorfer H, Landgraf B, Wiedermann G, Kollatriscg H, 1994. 
Inverse correlation of sensitivity  in vivo of  Plasmodium falci-
parum to chloroquine and mefloquine in Ghana.  Trans R Soc 
Trop Med Hyg 88: 443–444. 
 30.  Sowunmi A, Fateye BA, Adedeji AA, Fehintola FA, Gbotosho 
GO, Happi TC, Tambo E, Oduola AMJ, 2005. Predictors of the 
failure of treatment with chloroquine in children with acute, 
uncomplicated  Plasmodium falciparum malaria, in an area with 
high and increasing incidences of chloroquine resistance.  Trans 
R Soc Trop Med Hyg 99: 535–544. 
 31.  Fryauff DJ, Owusu-Agyei S, Utz G, Baird JK, Koram KA, Nkrumah 
F, Hoffman SL, 2006. Mefloquine treatment for uncomplicated 
falciparum malaria in young children 6–24 months of age in 
Northern Ghana.  Am J Trop Med Hyg 76: 224–231. 
 32.  Smithus F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M, 
Lindegardh N, Singtoroj T, Asley E, Lwin S, Stepniewska K, 
White NJ, 2006. Efficacy and effectiveness of dihydroartemisinin-
piperaquine versus artesunate-mefloquine in falciparum malaria: 
an open-label randomized comparison.  Lancet 367: 2075–2085. 
 33.  Piyaphanee W, Krudsood S, Tangpukdee N, Thanachartwet W, 
Silachamroon U, Phophak N, Duangdee C, Haoharn O, Faithong 
S, Wilairatana P, Leowattana W, Looaresuwan S, 2006. Emergence 
and clearance of gametocytes in uncomplicated  Plasmodium 
falciparum malaria.  Am J Trop Med Hyg 74: 432–435. 
 34.  Tangpukdee N, Krudsood S, Srivilairit S, Phophak N, Chonsawat P, 
Yanpanich W, Kano S, Wilairatana P, 2008. Gametocyte clear-
ance in uncomplicated and severe  Plasmodium falciparum 
malaria after artesunate-mefloquine treatment in Thailand. 
 Korean J Parasitol 46: 65–70. 
 35.  Bousema JT, Schneider P, Gougna LC, Drakeley CJ, Tostmann A, 
Houben R, Githure JI, Ord R, Sutherland CJ, Omar SA, 
Sauerwein RW, 2006. Moderate effect of artemisinin-based 
combination therapy on transmission of  Plasmodium falci-
parum.  J Infect Dis 193: 1151–1159. 
 36.  Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, 
Brockman A, McGready R, ter Kuile F, Looaresuwan S, White 
NJ, 2000. Effects of artesunate-mefloquine combination on 
incidence of  Plasmodium falciparum malaria and mefloquine 
resistance in western Thailand.  Lancet 356: 297–302. 
 37.  van Vugt M, Brockman A, Gemperll B, Luxemburger C, Gathmann 
I, Royce C, Slight T, Looaresuwan S, White NJ, Nosten F, 1998. 
Randomized comparison of artemether-benflumetol and arte-
sunate-mefloquine in the treatment of multidrug-resistant fal-
ciparum malaria.  Antimicrob Agents Chemother 42: 135–139. 
 38.  Marquino W, Hulca M, Galampa C, Falconi E, Cabezas C, Naupay 
R, Ruebush TK II, 2003. Efficacy of mefloquine and a meflo-
quine-artesunate combination therapy for the treatment of 
uncomplicated  Plasmodiun falciparum malaria in the Amazon 
Basin of Peru.  Am J Trop Med Hyg 68: 608–612. 
 39.  Krudsood S, Looaresuwan S, Silachamroon U, Chalermrut K, 
Pittron D, Cambon N, Mueller EA, 2002. Artesunate-mefloquine 
given simultaneously for three days via pre-packed blister is 
equally effective and tolerated as a standard sequential treat-
ment of uncomplicated acute  Plasmodium falciparum malaria: 
randomizes double-blind study in Thailand.  Am J Trop Med 
Hyg 67: 465–472. 
 40.  Hutagalung R, Paiphun L, Ashley EA, McGready R, Brockman 
A, Thwai KL, Singhasivanon P, Jelinek T, White NJ, Nosten 
FH, 2005. A randomized trial of artemether-lumefantrine ver-
sus mefloquine-artesunate for the treatment of uncomplicated 
multi-drug resistant  Plasmodium falciparum on the western 
border of Thailand.  Malar J 4: 46., doi: 10.11186/1475-2875-4.46. 
986 SOWUNMI AND OTHERS
 41.  Agomo PU, Meremikwu MM, Watila IM, Omalu IJ, Odey FA, 
Oguche S, Ezeiru VI, Aina OO, 2008. Efficacy, safety and toler-
ability of artesunate-mefloquine in the treatment of uncompli-
cated  Plasmodium falciparum malaria in four geographic zones 
of Nigeria.  Malaria J 7: 172. 
 42.  Wongsrichanalai C, Meshnick SR, 2008. Declining artesunate-
mefloquine efficacy against falciparum malaria on the Cam-
bodia-Thailand border.  Emerg Infect Dis 14: 716–719. 
 43.  Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends 
M, Brockman A, Anderson T, McGready R, Phaiphun L, 
Proux S, van Vugt M, Hutagalung R, Lwin KM, Phyo 
AP, Preechapornkul P, Imwong M, Pukrittayakamee S, 
Singhasivanon P, White NJ, Nosten F, 2009. Changes in the 
treatment responses to artesunate-mefloquine on the north-
western border of Thailand during 13 years of continuous 
deployment.  PLoS One 4: e4551. 
 44.  Dondorp AM, Nosten F, Poravuth Yi, Das D, Phyo AP, Tarning J, 
Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, 
Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An 
SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh K, Socheat 
D, White NJ, 2009. Artemisinin resistance in  Plasmodium falci-
parum.  New Eng J Med 361: 455–467. 
 45.  Barrett P, Emmins P, Clarke P, Bradley D, 1996. Comparison of 
adverse events associated with the use of mefloquine and combi-
nation of chloroquine and proguanil as antimalarial prophylaxis: 
postal and telephone survey of travelers.  BMJ 313: 525–528. 
 46.  Phillips M, Kass R, 1996. User acceptability patterns of meflo-
quine and doxycycline malaria chemoprophylaxis.  J Travel Med 
3: 10–15. 
 47.  Huzley D, 1996. Malaria chemoprophylaxis in German tourists: a 
prospective study on compliance and adverse reactions.  J Travel 
Med 3: 148–155. 
 48.  Schwartz E, Potasman I, Rotenberg I, Almog S, Sadetzski S, 2001. 
Serious adverse events of mefloquine in relation to blood level 
and gender.  Am J Trop Med Hyg 65: 189–192. 
 49.  Rendi-Wagner P, Noedl H, Wernsdorfer WH, Wiedermann G, 
Mikolasek A, Kollatrisch H, 2002. Unexpected frequency, dura-
tion and spectrum of adverse events after therapeutic dose of 
mefloqine in healthy adults.  Acta Trop 81: 167–173. 
 50.  van Remsdijk MM, Sturkenboom MCJM, Ditters JM, Tulen JHM, 
Lighthelm RJ, Overbosch D, Stricker BH, 2004. Low body mass 
index is associated with an increased risk of neuropsychiatric 
adverse events and concentration impairment in women on 
mefloquine.  Br J Clin Pharmacol 57: 506–512. 
 51.  Mattison D, Zajicek A, 2006. Gaps in knowledge in treating preg-
nant women.  Gend Med 3: 169–182. 
 52.  Sowunmi A, Salako LA, Oduola AMJ, Walker O, Akindele JA, 
Ogundahunsi OAT, 1993. Neuropsychiatric side effects of 
mefloquine in Africans.  Trans R Soc Trop Med Hyg 87: 
462–463. 
 53.  Chotivanich K, Udomsangpetch R, Dondorp A, Williams T, Angus 
B, Simpson JA, Pukrittayakamee S, Looaresuwan S, Newbold 
CI, White NJ, 2000. The mechanism of parasite clearance after 
antimalarial treatment of  Plasmodium falciparum malaria. 
 J Infect Dis 182: 629–633. 
 54.  Sowunmi A, Balogun ST, Gbotosho GO, Happi CT, 2009. Effects 
of amoqiauine, artesunate, and artesunate-amodiaquine on 
 Plasmodium falciparum malaria-associated anaemia in chil-
dren.  Acta Trop 109: 55–60. 
 55.  Obonyo CO, Taylor W, Ekvall H, Kaneko A, ter Kuile F, Olliaro P, 
Bjorkman A, Oloo AJ, 2007. Effects of artesunate plus sulfa-
doxine-pyrimethamine on haematological recovery and anae-
mia in Kenyan children with uncomplicated  Plasmodium 
falciparum malaria.  Ann Trop Med Parasitol 101: 281–295. 
